AstraZeneca said on Friday that its and Daiichi Sankyo’s cancer drug Enhertu has been recommended by the European Medicines Agency’s human medicines committee as a monotherapy to treat patients with a type of non-small cell lung cancer (NSCLC).
The recommendation is based on mid-stage data where Enhertu showed a confirmed objective response rate of 49% and a median duration of response of 16.8 months in patients previously treated for lung cancer.
EU ASSESSES HUMAN AND LABOR RIGHTS IN BURMA
CLICK HERE TO GET THE FOX NEWS APP
The drug is already approved in the European Union as a treatment for patients with advanced breast cancer.
The recommendations of the Committee for Medicinal Products for Human Use should be formally approved by the European Commission.